Developments in the treatment of candidiasis: more choices and new challenges
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The incidence of oesophageal candidiasis, candidaemia and disseminated candidiasis has increased dramatically. In addition to the amphotericin B formulations and fluconazole, the echinocandins anidulafungin, caspofungin and micafungin and the newer triazoles posaconazole and voriconazole are in the last stages of development and are becoming available for the management of candidiasis. This review presents these new agents and addresses their role in the treatment of candidiasis. All new antifungal agents exhibit potent activity against Candida spp. and echinocandins are fungicidal against most Candida spp. but appear to be less potent against certain species, such as Candida parapsilosis and C. guilliermondii. Systemic antifungal therapy can now be individualised based on the severity of the infection, comorbid conditions and the Candida spp. causing the infection. Studies are needed to investigate the possible development of resistance and the efficacy of these antifungal agents against the more resistant Candida spp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 2×
“New antifungal agents have become available for the treatment of Candida infections and more clinical data are available [94].”
BackgroundComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424 · cited 1×
“is the fourth most common cause of bloodstream infections [7].”
BackgroundDiekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385
Ally, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331 · cited 2×
“Voriconazole was equally as effective as fluconazole in the treatment of oesophageal candidiasis [88].”
BackgroundVillanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281 · cited 1×
“parapsilosis is the second most common cause of invasive candidiasis among paediatric patients [13-16].”
BackgroundPfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · cited 3×
“with a MIC of ≥ 4 as voriconazole resistant [59].”
BackgroundOstrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Ikeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., & Kuwahara, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.614-618.2000 · Cited by 147 · cited 1×
“[74] studied the efficacy of micafungin compared with amphotericin B and fluconazole in immunocompromised mice with disseminated candidiasis due to C.”
BackgroundTakakura, S. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh053 · Cited by 117 · cited 1×
“Invasive candidiasis has a significant impact on overall morbidity, mortality, hospital stay and cost [1,2].”
BackgroundPark, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113 · cited 1×
“Over the last 2 years, the Clinical and Laboratory Standards Institute has outlined a uniform methodology for the study of Candida susceptibility in vitro [93]; however, interpretive breakpoints are only available for fluconazole and voriconazole [59,94,95].”
BackgroundEstimating the Cost of Nosocomial Candidemia in the United States
Miller, L. G., Hajjeh, R. A., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/319613 · Cited by 109 · cited 1×
“In the USA, the cost attributable to candidaemia is approaching US$1 billion/year and a cost of illness analysis estimated the average cost of candidaemia for a single episode of care in 1997 to be US$34,123/Medicare patient and US$44,536/private insurance patient [11,12].”
BackgroundEmerging trends in the epidemiology of invasive mycoses in England and Wales (1990–9)
LAMAGNI, T. L., EVANS, B. G., SHIGEMATSU, M., & JOHNSON, E. M. (2001) · Epidemiology and Infection · doi:10.1017/s0950268801005507 · Cited by 104 · cited 1×
“The same trend was noted in the 1990s when the Communicable Disease Surveillance Center from England and Wales studied the laboratory reports of invasive mycoses from 1990 to 1999 [5].”
BackgroundActivities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp
Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S., Hollis, R. J., & Pfaller, M. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.324-326.2006 · Cited by 97
Ibrahim, A. S., Spellberg, B. J., Avenissian, V., Fu, Y., Filler, S. G., & Edwards, J. E. (2005) · Infection and Immunity · doi:10.1128/iai.73.2.999-1005.2005 · Cited by 83 · cited 1×
“The vaccine appears to stimulate TH1 lymphocytes and is protective in B-cell-deficient mice [102].”
BackgroundKilling Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondii
Cantón, E., Pemán, J., Sastre, M., Romero, M., & Espinel-Ingroff, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00524-06 · Cited by 37
Cited by
A nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343
Self-citationFontenelle, R. O. S., Morais, S. M., Brito, E. H. S., Kerntopf, M. R., Brilhante, R. S. N., Cordeiro, R. A., Tomé, A. R., Queiroz, M. G. R., Nascimento, N. R. F., Sidrim, J. J. C., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm066 · Cited by 181
Confronting the challenges of natural product-based antifungal discovery
Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., & Bills, G. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.009 · Cited by 147
“Antifungal Target Identification and Validation Pathogenic fungi, especially Candida species, have emerged as important and prevalent opportunistic pathogens infecting patients with compromised immunity, including transplant recipients, cancer patients, and those suffering from AIDS (Aperis et al., 2006).”
Background
Metadata
- Authors
- Aperis, G., Myriounis, N., Spanakis, E. K., & Mylonakis, E.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2006-10-16
- Volume
- 15
- Issue
- 11
- Pages
- 1319-1336
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2098731984
- Cited by
- 56
- References
- 22
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.